Foghorn Therapeutics
FHTX
60 hedge funds and large institutions have $357M invested in Foghorn Therapeutics in 2022 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 20 increasing their positions, 14 reducing their positions, and 12 closing their positions.
43% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 14
3.24% more ownership
Funds ownership: 60.13% → 63.36% (+3.2%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 12
2% less funds holding
Funds holding: 61 → 60 (-1)
6% less capital invested
Capital invested by funds: $379M → $357M (-$21.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$6.95M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.79M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.07M |
| 4 |
Morgan Stanley
New York
|
+$2.49M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$892K |
| 2 |
KCM
Kingdon Capital Management
New York
|
-$826K |
| 3 |
Nuveen
Charlotte,
North Carolina
|
-$687K |
| 4 |
BlackRock
New York
|
-$425K |
| 5 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$396K |
FHTX Hedge Fund Activity: Q2 2022 in Review
60 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Foghorn Therapeutics (FHTX) for Q2 2022, worth a combined $357M — down 5.7% from $379M a quarter earlier.
Fund positioning in FHTX was balanced in Q2 2022: 12 funds opened new positions, 12 closed out, 20 added to existing stakes and 14 trimmed.
The largest buyer was Deerfield Management, adding an estimated $6.95M. The largest seller was Citadel Advisors, exiting entirely with an estimated $892K sold.
- 60 institutional investors held Foghorn Therapeutics (FHTX) as of Q2 2022, down from 61 in Q1 2022.
- Funds reported $357M of Foghorn Therapeutics stock for Q2 2022, down 5.7% quarter-over-quarter.
- 12 funds opened new Foghorn Therapeutics positions in Q2 2022 and 12 closed out, a net change of 0 holders.
- The largest Foghorn Therapeutics buyer in Q2 2022 was Deerfield Management, an estimated $6.95M added.
- The largest Foghorn Therapeutics seller in Q2 2022 was Citadel Advisors, an estimated $892K sold.
Based on aggregated 13F filings for Q2 2022.